TAKEDA PHARMACEUTICAL COMPANY LIMITED;다케다 야쿠힌 고교 가부시키가이샤
发明人:
YAMAMOTO KATSUHIKO,야마모토 가츠히코
申请号:
KR1020137034952
公开号:
KR1020140040777A
申请日:
2012.06.21
申请国别(地区):
KR
年份:
2014
代理人:
摘要:
The present invention relates to a crystal of 1-ethyl-7-methyl-3-{4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)oxy]phenyl}-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one useful as a prophylactic or therapeutic agent for schizophrenia and the like, which shows an X-ray powder diffraction pattern having characteristic peaks at interplaner spacings (d) of 13.59 plus or minus 0.2 and 6.76 plus or minus 0.2 Angstroms in powder X-ray diffraction.본 발명은 분말 X-선 회절에서 격자면 간격 (d) 13.59±0.2 및 6.76±0.2 옹스트롬에 특징적 피크를 갖는 X-선 분말 회절 패턴을 나타내는, 정신분열병 등의 예방 또는 치료제로서 유용한 1-에틸-7-메틸-3-{4-[(3-메틸-3H-이미다조[4,5-b]피리딘-2-일)옥시]페닐}-1,3-디히드로-2H-이미다조[4,5-b]피리딘-2-온의 결정에 관한 것이다.